Abstract:Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease. However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients. Methods Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay. Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2. The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time. Findings SARS-CoV-2 NAbs were unable to cross-reactive with SARS-CoV virus. SARS-CoV-2-specific NAbs were detected in patients from day 10-15 after the onset of the disease and remained thereafter. The titers of NAb among these patients correlated with the spike-binding antibodies targeting S1, RBD, and S2 regions. The titers of NAbs were variable in different patients. Elderly and middle-age patients had significantly higher plasma NAb titers (P<0.0001) and spike-binding antibodies (P=0.0003) than young patients. Notably, among these patients, there were ten patients whose NAb titers were under the detectable level of our assay (ID50: < 40); while in contrast, two patients, showed very high titers of NAb, with ID50 :15989 and 21567 respectively. The NAb titers were positive correlated with plasma CRP levels but negative correlated with the lymphocyte counts of patients at the time of admission, indicating an association between humoral response and cellular immune response. Interpretation The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may raise the concern about the role of NAbs on disease progression. The correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored for the development of effective vaccine against SARS-CoV-2 virus. Furthermore, titration of NAb is helpful prior to the use of convalescent plasma for prevention or treatment. Funding Ministry of Science and Technology of China, National Natural Science Foundation of China, Shanghai Municipal Health Commission, and Chinese Academy of Medical Sciences

Neutralizing antibodies for the treatment of COVID-19

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Neutralizing monoclonal antibodies for treatment of COVID-19

COVID-19 neutralizing antibodies predict disease severity and survival

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

COVID-19-neutralizing antibodies predict disease severity and survival

Neutralization of SARS-CoV-2 Infection by Antibodies Targeting Diverse Epitopes

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

Neutralizing Antibodies: the Elite Squad to Combat SARS-CoV-2 Infection

Neutralizing Monoclonal Antibodies Present New Prospects to Treat SARS-CoV-2 Infections

Opportunities and Challenges to the Use of Neutralizing Monoclonal Antibody Therapies for COVID-19

[Sars-Cov-2 Neutralizing Monoclonal Antibodies and Nanobodies: a Review].

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Antibodies for COVID-19 - which, when and how long?

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials

Profiling B cell immune responses to identify neutralizing antibodies from convalescent COVID 19 patients

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Antibody-Based Immunotherapeutic Strategies for COVID-19